Illustration of a heart with interconnected pathways, symbolizing systemic right ventricle and hope for long-term heart health.

Beyond the Trial: How Valsartan Impacts Long-Term Heart Health in Congenital Conditions

Soraya Malik monogram
Soraya Malik in Health & Wellness October 2026 • 5 min read.

"New research reveals the extended effects of valsartan on patients with systemic right ventricle, offering insights into managing congenital heart conditions and improving long-term outcomes."


Congenital heart defects, particularly those resulting in a systemic right ventricle (RV), pose significant long-term challenges. These conditions, often stemming from corrected transposition of the great arteries (TGA), can lead to gradual heart failure and increased morbidity. Managing these complex cases requires a nuanced approach, and researchers are continually exploring the role of medications like valsartan in improving patient outcomes.

Valsartan, an angiotensin II receptor blocker, has been investigated for its potential to improve heart function in patients with systemic RV. Initial studies, such as the VAL-SERVE trial, showed promise in improving ventricular function, especially in symptomatic individuals. However, the long-term effects of valsartan have remained an area of ongoing research.

A recent study published in the International Journal of Cardiology delves deeper into the extended clinical outcomes of valsartan treatment. By following patients over a longer period, researchers aimed to determine whether the early benefits of valsartan translate into sustained improvements in survival and overall heart health. This article will unpack the findings of this study, offering clear insights into who might benefit most from valsartan and what it means for managing congenital heart conditions.

AI Search Multiple angles on this topic

The Burden of Heart Failure in Congenital Heart Disease

Heart failure remains a significant cause of morbidity and mortality among individuals living with congenital heart disease, though precise prevalence figures vary across studies and populations. As surgical outcomes improve and more patients survive into adulthood, the long-term cardiovascular consequences of congenital conditions are becoming an increasingly important area of clinical focus. Estimates suggest that heart failure affects a substantial minority of the growing adult congenital heart disease population, though exact percentages depend on the specific defect and patient characteristics.

Therapeutic Gaps in Congenital Heart Disease Management

While clinical guidelines for acquired cardiovascular diseases exist, evidence-based therapies specifically for heart failure in congenital heart disease remain largely lacking. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has demonstrated efficacy in adults with heart failure due to structurally normal hearts, yet its tolerability and outcomes in the adult congenital heart disease population are not well characterized. This gap is significant because heart failure represents one of the leading complications among congenital heart disease patients, driving substantial morbidity and mortality.

The Development of Valsartan as a Therapeutic Agent

Valsartan, marketed under the brand name Diovan among others, is an angiotensin II receptor blocker (ARB) used to treat high blood pressure, heart failure, and diabetic kidney disease. The development of valsartan represented a significant step forward in cardiovascular pharmacology, having been first patented in 1990 and introduced for medical use in 1996. Clinical evidence has established that valsartan is effective in treating hypertension and is similarly effective as angiotensin-converting enzyme (ACE) inhibitors following myocardial infarction accompanied by left ventricular dysfunction and/or heart failure.

Valsartan and the Systemic Right Ventricle: What the Study Revealed

Illustration of a heart with interconnected pathways, symbolizing systemic right ventricle and hope for long-term heart health.

The study, a follow-up to the VAL-SERVE trial, examined 88 adults with TGA who were initially randomized to receive either valsartan or a placebo for three years. Researchers tracked these patients for an average of 8.3 years after the trial's conclusion, gathering data on their cardiac health, medication use, and survival rates. This long-term perspective allowed for a comprehensive assessment of valsartan's impact beyond the initial treatment period.

The results indicated that while valsartan did not significantly improve overall survival in the entire group, it did show a notable benefit for symptomatic patients. Specifically, valsartan was associated with a decreased risk of clinical events, such as arrhythmia, heart failure, tricuspid valve surgery, and death, in those who were symptomatic at the start of the study. This suggests that valsartan may play a crucial role in managing heart failure symptoms and improving the quality of life for specific patient subgroups.

  • No Overall Survival Benefit: Valsartan did not improve overall survival rates across the entire study group.
  • Reduced Risk for Symptomatic Patients: Symptomatic patients experienced a significant reduction in the risk of adverse clinical events.
  • Consistent Cardiac Drug Use: Cardiac drug use and follow-up were similar between the valsartan and placebo groups.
  • Mortality Causes: Deaths were primarily attributed to heart failure and related complications.
AI Search Multiple angles on this topic

Emerging Evidence for Sacubitril/Valsartan in Congenital Heart Disease

Recent studies published in 2025 have begun to address the evidence gap regarding sacubitril/valsartan use in congenital heart disease populations, with researchers reporting single-center experiences and outcomes data. While the efficacy and safety of ARNI therapy in the general heart failure population is well documented, data specific to the congenital heart disease cohort remain limited according to investigators. The growing body of literature reflects increasing clinical interest in optimizing heart failure management for this historically underserved patient group.

Limitations and Unresolved Questions

Despite growing interest in repurposing sacubitril/valsartan for congenital heart disease-related heart failure, important questions remain about long-term efficacy and safety in this population. The absence of randomized controlled trials specifically designed for congenital heart disease patients means that clinicians must rely on observational data and extrapolation from studies conducted in structurally normal hearts. Concerns persist about whether benefits observed in acquired heart failure will translate meaningfully to the heterogeneous anatomical and physiological profiles seen in congenital conditions.

Sacubitril/Valsartan Versus Conventional ACE Inhibitor/ARB Therapy

A comparative analysis of sacubitril-valsartan versus traditional ACE inhibitor/ARB therapy in pediatric heart failure patients with congenital heart disease history found no statistically significant difference in primary outcomes between the two treatment approaches. Specifically, the primary outcome occurred in 36 of 217 patients treated with sacubitril-valsartan and 37 of 216 patients treated with ACE/ARB, representing rates of 16.6% versus 17.1% respectively (p = 0.88). These findings suggest that sacubitril-valsartan may offer comparable rather than clearly superior outcomes to established renin-angiotensin system inhibitors in this specific population.

The study also explored the use of other medications, such as ACE inhibitors and beta-blockers, during the follow-up period. The researchers found no significant differences in the use of these drugs between the valsartan and placebo groups, suggesting that the observed benefits in symptomatic patients were likely due to the specific effects of valsartan rather than other medications. Further analysis indicated that valsartan's positive impact was consistent, even when considering the use of other renin-angiotensin-aldosterone system (RAAS) inhibitors.

The Bottom Line: Personalizing Treatment for Congenital Heart Conditions

This research underscores the importance of personalized treatment strategies for individuals with congenital heart conditions. While valsartan may not be a universal solution, it appears to offer significant benefits for symptomatic patients with a systemic RV. By identifying those who are most likely to benefit, clinicians can make more informed decisions about medication use, ultimately improving patient outcomes and quality of life. Further studies are needed to refine these strategies and explore additional interventions that can support long-term heart health in this vulnerable population.

AI Search Multiple angles on this topic

Quality of Life Improvements with Sacubitril/Valsartan

Research has demonstrated short-term improvements in quality of life among adult congenital heart disease patients with systemic right ventricle failure following treatment with sacubitril/valsartan. investigators have aimed to evaluate whether these quality of life benefits persist over the medium term, recognizing that sustained functional improvement is critical for patient-centered outcomes in chronic heart failure management. The focus on quality of life metrics reflects a growing recognition that survival endpoints alone may not capture the full impact of therapeutic interventions in congenital heart disease populations.

Research Priorities and Clinical Directions

The current evidence base for sacubitril/valsartan in congenital heart disease remains in its early stages, with most data coming from single-center experiences and small cohorts. Future research priorities likely include larger multi-center studies, longer follow-up periods, and investigation of outcomes across specific congenital heart disease subtypes. As the adult congenital heart disease population continues to grow, the need for evidence-based heart failure management strategies tailored to this population will only intensify.

Systemic Barriers to Evidence Generation

Developing evidence-based therapies for heart failure in congenital heart disease faces inherent challenges related to patient heterogeneity, relatively small population sizes, and the complexity of underlying anatomical variations. These factors make large-scale randomized controlled trials particularly difficult to conduct, contributing to the persistent gap between available evidence and clinical need. Addressing these barriers will likely require innovative trial designs, international collaboration, and integration of real-world data sources.

Patient Experiences and Clinical Decision-Making

For adults living with congenital heart disease who develop heart failure, the availability of emerging therapeutic options like sacubitril/valsartan represents both hope and uncertainty. Clinicians must balance the potential benefits of newer agents against limited congenital-specific evidence, often making treatment decisions based on extrapolation from acquired heart disease populations. The human impact of these decisions underscores the importance of continuing to build a robust evidence base that can guide more confident clinical practice in this vulnerable patient group.

Valsartan's measured effects in context

  • 15 mL larger increase in placebo groupCompared with valsartan, the placebo group had a 15 mL larger increase in right ventricular end-diastolic volume and an 8 g larger increase in mass. These between-group differences were statistically significant.[1]

What the results add-and do not establish

The long-term findings do not show a general advantage across the randomized groups on clinical endpoints, but they do point to a different pattern among participants who were symptomatic: their event risk was lower with valsartan than with placebo. This subgroup result does not establish that the same benefit applies to everyone with a systemic right ventricle.[2]

Earlier measures of exercise capacity and quality of life did not show significant treatment effects, while the placebo group had larger increases in ventricular volume and mass. Taken together, these measures describe differences in some aspects of heart remodeling without demonstrating broad improvement in function or day-to-day wellbeing.[1]

How valsartan fits the wider right-heart evidence

The long-term comparison reports no difference in clinical endpoints between the original treatment groups overall, even as the symptomatic subgroup showed a lower event risk. That contrast makes symptom status an important boundary on how broadly the result can be read.[2]

A separate analysis found beta-blockers, ACE inhibitors, and ARBs were not associated with differences in the composite outcome or heart-failure hospitalizations after propensity-score adjustment. This is a medication-class comparison, not a direct replication of the valsartan subgroup finding.[3]

The clinical rationale also has a biological boundary: therapies used for acquired left-heart failure are often applied in congenital right-heart failure, although the ventricles differ substantially and evidence for that strategy is lacking. Right-heart failure is described as a main cause of death in this context.[4]

Questions left by the valsartan evidence

  • Can conclusions about valsartan be extended to sacubitril/valsartan in symptomatic systemic right-ventricle dysfunction, given that premature interruption of PARACYS-RV prevented firm conclusions about that therapy?[5]

Sources

  1. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. (pubmed.ncbi.nlm.nih.gov)
  2. Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: Follow-up of a multicenter randomized controlled trial. (pubmed.ncbi.nlm.nih.gov)
  3. Propensity Score Analysis of Possible Medication Effects on Outcomes in Patients With Systemic Right Ventricles (pmc.ncbi.nlm.nih.gov)
  4. The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease (pmc.ncbi.nlm.nih.gov)
  5. Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is the primary focus of this research regarding valsartan?

The primary focus is on the long-term effects of valsartan in patients with a systemic right ventricle (RV), particularly those with congenital heart conditions like corrected transposition of the great arteries (TGA). The research investigates whether the early benefits observed in trials like VAL-SERVE translate into sustained improvements in survival and overall heart health over an extended period of time.

2

How does valsartan impact patients with a systemic right ventricle (RV) differently compared to those without symptoms?

The study showed a significant difference in valsartan's impact based on symptoms. While valsartan did not improve overall survival rates across the entire group, it notably benefited symptomatic patients. These patients experienced a decreased risk of adverse clinical events such as arrhythmia, heart failure, tricuspid valve surgery, and death. This suggests that valsartan is more effective for symptomatic individuals.

3

What were the key findings regarding the use of valsartan in managing patients with congenital heart conditions?

The key findings include: valsartan did not significantly improve overall survival rates across the entire study group; symptomatic patients experienced a significant reduction in the risk of adverse clinical events; cardiac drug use, including ACE inhibitors and beta-blockers, was similar between the valsartan and placebo groups, suggesting the benefits were likely due to valsartan itself. Deaths were primarily attributed to heart failure and related complications.

4

Can valsartan be considered a universal solution for all congenital heart conditions, and what does the study suggest about personalized treatment?

No, valsartan is not a universal solution. The research underscores the importance of personalized treatment strategies. While valsartan did not show overall survival benefits for all patients, it offered significant advantages for symptomatic patients with a systemic RV. This highlights the need for clinicians to identify the patient subgroups most likely to benefit from valsartan to improve outcomes and quality of life, leading to a more tailored approach to medication use.

5

How does this research on valsartan contribute to the ongoing management of congenital heart conditions like TGA?

This research provides valuable insights into the use of valsartan in managing complex congenital heart conditions, especially those involving a systemic RV. It suggests that valsartan can play a crucial role in managing heart failure symptoms and improving the quality of life, especially for symptomatic patients. By understanding who benefits most, clinicians can make more informed decisions, potentially improving patient outcomes. The findings highlight the need for continued research to refine treatment strategies and explore additional interventions that can support long-term heart health in this vulnerable population.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.